Literature DB >> 25415070

Treatment by specialist surgical neurooncologists improves survival times for patients with malignant glioma.

Ursalan A Khan1, Amar Bhavsar, Hasan Asif, Konstantina Karabatsou, James R S Leggate, Ajit Sofat, Ian D Kamaly-Asl.   

Abstract

OBJECT: Surgeries for CNS tumors are frequently performed by general neurosurgeons and by those who specialize in surgical neurooncology. Subspecialization in neurosurgical practice has become common and may improve patient morbidity and mortality rates. However, the potential benefits for patients of having their surgeries performed by surgical neurooncologists remain unclear. Recently, a shift in patient care to those who practice predominantly surgical neurooncology has been promoted. Evidence for this practice is lacking and therefore requires fundamental investigation.
METHODS: The authors conducted a case-control study of neurooncology patients who underwent surgery for glioblastoma and anaplastic astrocytoma during 2006-2009. Outcomes were compared for patients whose surgery was performed by general neurosurgeons (generalists) or by specialist neurooncology neurosurgeons (specialists). An electronic record database and a picture archiving and communication system were used to collect data and assess the extent of tumor resection. Mortality rates and survival times were compared. Patient comorbidity and postoperative morbidity were assessed by using the Waterlow, patient handling, and falls risk assessment scores. Effects of case mix were adjusted for by using Cox regression and a hazards model.
RESULTS: Outcomes for 135 patients (65 treated by generalists and 70 by specialists) were analyzed. Survival times were longer for patients whose surgery was performed by specialists (p=0.026) and after correction for case mix (p=0.019). Extent of tumor resection was greater when performed by specialists (p=0.005) and correlated with increased survival times (p=0.004). There was a trend toward reduced surgical deaths when surgery was performed by specialists (2.8%) versus generalists (7%) (p=0.102), and inpatient stays were significantly shorter when surgery was performed by specialists (p=0.008).
CONCLUSIONS: The prognosis for glioblastoma multiforme remains dire, and improved treatments are urgently needed. This study provides evidence for a survival benefit when surgery is performed by specialist neurooncology neurosurgeons. The benefit might be attributable to increased tumor resection. Furthermore, specialist neurooncology surgical care may reduce the number of surgical patient deaths and length of inpatient stay. These findings support the recommendations for subspecialization within surgical neurooncology and advocate for care of these patients by specialists.

Entities:  

Keywords:  AA = anaplastic astrocytoma; GBM = glioblastoma multiforme; MRC = Medical Research Council; glioblastoma multiforme; glioma; neurooncology; oncology; subspecialization

Mesh:

Year:  2014        PMID: 25415070     DOI: 10.3171/2014.10.JNS132057

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  9 in total

1.  MiR-302c-3p suppresses invasion and proliferation of glioma cells via down-regulating metadherin (MTDH) expression.

Authors:  Yonghong Wang; Yujun Wei; Haibo Tong; Laizhao Chen; Yimin Fan; Yuchen Ji; Wenqing Jia; Dongkang Liu; Guihuai Wang
Journal:  Cancer Biol Ther       Date:  2015-07-15       Impact factor: 4.742

2.  Long non-coding RNA XIST exerts oncogenic functions in human glioma by targeting miR-137.

Authors:  Zong Wang; Jiangwei Yuan; Li Li; Yang Yang; Xuchang Xu; Ying Wang
Journal:  Am J Transl Res       Date:  2017-04-15       Impact factor: 4.060

3.  Is a pretreatment radiological staging system feasible for suggesting the optimal extent of resection and predicting prognosis in glioblastoma? An observational study.

Authors:  Jaume Capellades; Josep Puig; Sira Domenech; Teresa Pujol; Laura Oleaga; Angels Camins; Carles Majós; Rocio Diaz; Christian de Quintana; Pilar Teixidor; Gerard Conesa; Gerard Plans; Josep Gonzalez; Natalia García-Balañà; Jose Maria Velarde; Carmen Balaña
Journal:  J Neurooncol       Date:  2017-12-28       Impact factor: 4.130

4.  Increased pediatric sub-specialization is associated with decreased surgical complication rates for inpatient pediatric urology procedures.

Authors:  R Tejwani; H-H S Wang; B J Young; N H Greene; S Wolf; J S Wiener; J C Routh
Journal:  J Pediatr Urol       Date:  2016-06-16       Impact factor: 1.830

5.  Extent of Resection in Newly Diagnosed Glioblastoma: Impact of a Specialized Neuro-Oncology Care Center.

Authors:  Amer Haj; Christian Doenitz; Karl-Michael Schebesch; Denise Ehrensberger; Peter Hau; Kurt Putnik; Markus J Riemenschneider; Christina Wendl; Michael Gerken; Tobias Pukrop; Alexander Brawanski; Martin A Proescholdt
Journal:  Brain Sci       Date:  2017-12-25

6.  STAT3 promotes tumour progression in glioma by inducing FOXP1 transcription.

Authors:  Xinlin Sun; Jihui Wang; Min Huang; Taoliang Chen; Jiansheng Chen; Fabing Zhang; Huijun Zeng; Zhimin Xu; Yiquan Ke
Journal:  J Cell Mol Med       Date:  2018-08-22       Impact factor: 5.310

7.  Mir-338-3p Inhibits Malignant Biological Behaviors of Glioma Cells by Targeting MACC1 Gene.

Authors:  Chao Shang; Yang Hong; Yan Guo; Yi-xue Xue
Journal:  Med Sci Monit       Date:  2016-03-03

8.  miR-6743-5p, as a direct upstream regulator of GRIM-19, enhances proliferation and suppresses apoptosis in glioma cells.

Authors:  Fang Cao; Qiang Zhang; Wei Chen; Feng Zheng; Qishan Ran; Yang He; Yang Gao; Shengtao Yao
Journal:  Biosci Rep       Date:  2017-12-12       Impact factor: 3.840

9.  The long non-coding RNA SNHG14 inhibits cell proliferation and invasion and promotes apoptosis by sponging miR-92a-3p in glioma.

Authors:  Qiang Wang; Yiwan Teng; Rong Wang; Danni Deng; Yijie You; Ya Peng; Naiyuan Shao; Feng Zhi
Journal:  Oncotarget       Date:  2018-01-04
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.